Zhishin

Zhishin is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company's primary focus is on developing next-generation targeted therapies that address resistance mechanisms in cancer, particularly in non-small cell lung cancer (NSCLC). Its lead program, ZS-01, is a potent and selective EGFR tyrosine kinase inhibitor currently in clinical development. Zhishin leverages its internal medicinal chemistry expertise and drug discovery platform to build a robust pipeline of candidates targeting various oncogenic drivers. The company aims to provide precision medicine solutions to patients with significant unmet medical needs in both Chinese and global markets.